Accounting for susceptibility in risk assessment: The need for full disclosure

By Fowle III J.R.  

Environmental Toxicology and Pharmacology, Vol. 4, Iss. 3, 1997-12 ,pp. : 247-250

Elsevier

Access to resources Recommend Favorite

A Unified Approach to Risk Assessment for Cancer and Noncancer Endpoints Based on Benchmark Doses and Uncertainty/Safety Factors1

By Gaylor D.W.   Kodell R.L.   Chen J.J.   Krewski D.  

Regulatory Toxicology and Pharmacology, Vol. 29, Iss. 2, 1999-04 ,pp. : 151-157

Academic Press

Access to resources Recommend Favorite

Metabolomics Approach to Risk Assessment: Methoxyclor Exposure in Rats

By Kim Kyu-Bong   Kim Seon Hwa   Um So Young   Chung Myeon Woo   Oh Ji Seon   Jung Seung-Chul   Kim Tae Sung   Moon Hyun Joo   Han Soon Young   Oh Hye Young   Lee Byung Mu   Choi Ki Hwan  

Journal of Toxicology and Environmental Health, Vol. 72, Iss. 21-22, 2009-01 ,pp. : 1352-1368

Taylor & Francis Ltd

Access to resources Recommend Favorite

Benefit-Risk Assessment of Irinotecan in Advanced Colorectal Cancer

By Glimelius Bengt  

Drug Safety, Vol. 28, Iss. 5, 2005-01 ,pp. : 417-433

Adis International

Access to resources Recommend Favorite

Benefit-Risk Assessment of Bevacizumab in the Treatment of Breast Cancer

By Dienstmann Rodrigo  

Drug Safety, Vol. 35, Iss. 1, 2012-01 ,pp. : 15-25

Adis International

Access to resources Recommend Favorite